172 related articles for article (PubMed ID: 37388735)
1. High DNA methylation age deceleration defines an aggressive phenotype with immunoexclusion environments in endometrial carcinoma.
Hao J; Liu T; Xiu Y; Yuan H; Xu D
Front Immunol; 2023; 14():1208223. PubMed ID: 37388735
[TBL] [Abstract][Full Text] [Related]
2. DNA Methylation Age Drift Is Associated with Poor Outcomes and De-Differentiation in Papillary and Follicular Thyroid Carcinomas.
Liu T; Wang J; Xiu Y; Wu Y; Xu D
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638311
[TBL] [Abstract][Full Text] [Related]
3. Telomerase May Paradoxically Accelerate Aging of the DNA Methylome.
Mendelsohn AR; Larrick JW
Rejuvenation Res; 2018 Apr; 21(2):168-172. PubMed ID: 29667924
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria and aging in older individuals: an analysis of DNA methylation age metrics, leukocyte telomere length, and mitochondrial DNA copy number in the VA normative aging study.
Dolcini J; Wu H; Nwanaji-Enwerem JC; Kiomourtozlogu MA; Cayir A; Sanchez-Guerra M; Vokonas P; Schwarz J; Baccarelli AA
Aging (Albany NY); 2020 Feb; 12(3):2070-2083. PubMed ID: 32009007
[No Abstract] [Full Text] [Related]
5. Epigenetic clocks provide clues to the mystery of uterine ageing.
Deryabin PI; Borodkina AV
Hum Reprod Update; 2023 May; 29(3):259-271. PubMed ID: 36515535
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation age in paired tumor and adjacent normal breast tissue in Chinese women with breast cancer.
Koka H; Bodelon C; Horvath S; Lee PMY; Wang D; Song L; Zhang T; Hurson AN; Guida JL; Zhu B; Bailey-Whyte M; Wang F; Wu C; Tsang KH; Tsoi YK; Chan WC; Law SH; Hung RKW; Tse GM; Yuen KK; Karlins E; Jones K; Vogt A; Zhu B; Hutchinson A; Hicks B; Garcia-Closas M; Chanock S; Barnholtz-Sloan J; Tse LA; Yang XR
Clin Epigenetics; 2023 Mar; 15(1):55. PubMed ID: 36991516
[TBL] [Abstract][Full Text] [Related]
7. Dysfunctional epigenetic aging of the normal colon and colorectal cancer risk.
Wang T; Maden SK; Luebeck GE; Li CI; Newcomb PA; Ulrich CM; Joo JE; Buchanan DD; Milne RL; Southey MC; Carter KT; Willbanks AR; Luo Y; Yu M; Grady WM
Clin Epigenetics; 2020 Jan; 12(1):5. PubMed ID: 31900199
[TBL] [Abstract][Full Text] [Related]
8. DNMT3A/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The Cancer Genome Atlas.
He D; Wang X; Zhang Y; Zhao J; Han R; Dong Y
Chin Med J (Engl); 2019 Jan; 132(2):161-170. PubMed ID: 30614867
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
10. Estimating breast tissue-specific DNA methylation age using next-generation sequencing data.
Castle JR; Lin N; Liu J; Storniolo AMV; Shendre A; Hou L; Horvath S; Liu Y; Wang C; He C
Clin Epigenetics; 2020 Mar; 12(1):45. PubMed ID: 32164769
[TBL] [Abstract][Full Text] [Related]
11. The influences of DNA methylation and epigenetic clocks, on metabolic disease, in middle-aged Koreans.
Lee HS; Park T
Clin Epigenetics; 2020 Oct; 12(1):148. PubMed ID: 33059731
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
Pasanen A; Loukovaara M; Bützow R
Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377
[TBL] [Abstract][Full Text] [Related]
13. Gene Promoter Methylation in Endometrial Carcinogenesis.
Cornel KMC; Wouters K; Van de Vijver KK; van der Wurff AAM; van Engeland M; Kruitwagen RFPM; Pijnenborg JMA
Pathol Oncol Res; 2019 Apr; 25(2):659-667. PubMed ID: 30430425
[TBL] [Abstract][Full Text] [Related]
14. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
16. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.
Chen SMY; Popolizio V; Woolaver RA; Ge H; Krinsky AL; John J; Danis E; Ke Y; Kramer Y; Bian L; Nicklawsky AG; Gao D; Liu S; Chen Z; Wang XJ; Wang JH
J Exp Clin Cancer Res; 2022 Apr; 41(1):123. PubMed ID: 35366939
[TBL] [Abstract][Full Text] [Related]
17. Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma.
Li S; Dong C; Chen J; Gao X; Xie X; Zhang X
Aging (Albany NY); 2021 Jun; 13(12):16696-16712. PubMed ID: 34158412
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide DNA methylation profile of early-onset endometrial cancer: its correlation with genetic aberrations and comparison with late-onset endometrial cancer.
Makabe T; Arai E; Hirano T; Ito N; Fukamachi Y; Takahashi Y; Hirasawa A; Yamagami W; Susumu N; Aoki D; Kanai Y
Carcinogenesis; 2019 Jul; 40(5):611-623. PubMed ID: 30850842
[TBL] [Abstract][Full Text] [Related]
20. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
